Amanita, ASEC filings state both of CDEX's ValiMed systems provide a recurring revenue stream. I believe both the CCT and the VG4 are described as being alive and well.
I suspect they only need show the VG4 working with various drugs in various bags, vials, and syringes to have trade show success continue to grow. The CCT is still available from what I see, but it seems the VG4 is positioned to eclipse it entirely.
Both provide a recurring revenue stream
FORM 10-Q
ValiMed™ Medication Validation System (MVS) Product Line – Consists of two products:
Our third generation ValiMed known as the ValiMed CCT and the ValiMed G4 system (VG4).
Both Valimed systems help healthcare providers ensure patient safety and control costs by reducing medication errors,
utilizing our patented and patent pending process known as Enhanced Photoemission Spectroscopy (EPS).
The VG4 system uses a patented detection process providing a real time (within seconds), quantitative (strength/concentration) as well as
qualitative (identification of an unknown) analysis of high-risk single component compounded medications and treatment solutions.
The Valimed CCT system that is operating in numerous hospital settings around the country, provides the healthcare industry with verification of a known substance, specifically a known drug with a known strength/concentration, in a known diluent. This current system also utilizes our proprietary cuvettes in the process. Both devices help healthcare facilities comply with Joint Commission on Accreditation of Healthcare Organizations compliance requirements and United States Pharmacopeia's General Chapter 797 Pharmaceutical Compounding—Sterile Preparations (“USP 797”) guidelines for compounding sterile preparations. Both product lines provide a recurring revenue stream and address three problem areas in the healthcare market: (i) human error in the compounding of medications, with an emphasis on, but not limited to high risk medications; (ii) harmful counterfeit medications and (iii) diversion of hospital narcotics. In the near future, we expect the VG4 product line to address multi component compounded mixtures, such as total parenteral nutrition. We expect to add oncology drugs to our formulary in 2013 as well.
One of the most significant improvements with the VG4 is the capability of analyzing through most containers that are currently being
used in pharmaceutical settings. This provides our end users with a more streamlined application, with less labor, without any compromising of the sterility of the compounded admixtures.
